Work

Narcolepsy Type 1: Should We Only Target Hypocretin Receptor 2?

Year: 2023

Type: article

Abstract: Nearly 25 years have passed since the ground-breaking discovery that hypocretin deficiency underlies human narcolepsy with cataplexy. Over time, it has become increasingly evident that hypocretin deficiency goes beyond the conventional core symptoms, or pentad, traditionally associated with narcolepsy. The emergence of hypocretin receptor 2 agonists presents an exciting opportunity, prompting us to explore the role of receptor 2 in the complete spectrum of NT1 symptoms. In this review, several clinical manifestations beyond the core symptoms will be discussed. We will outline what is currently known about the involvement of hypocretin receptors to reflect on what we expect with current knowledge from treatment with specific receptor agonists.

Source: Clinical and Translational Neuroscience

DOI: 10.3390/ctn7030028

Authors: Rolf Fronczek, Gert Jan Lammers

Institutions: Leiden University, Leiden University Medical Center, Stichting Epilepsie Instellingen Nederland

Language: English

Topic: Sleep and Wakefulness Research

Subfield: Cognitive Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,112